Back to Search Start Over

Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study

Authors :
Chiara Suffritti
Roberta Gualtierotti
Sara Arcudi
Alessandro Ciavarella
Cristina Novembrino
Anna Lecchi
Silvia La Marca
Lidia Padovan
Erica Scalambrino
Marigrazia Clerici
Patrizia Bono
Ferruccio Ceriotti
Antonio Muscatello
Simona Maria Siboni
Flora Peyvandi
Source :
Journal of Clinical Medicine, Vol 12, Iss 17, p 5475 (2023)
Publication Year :
2023
Publisher :
MDPI AG, 2023.

Abstract

To characterize the immunogenicity of mRNA-1273 (Moderna, Cambridge, MA, USA) vaccine in HIV-positive hemophilic patients during the third COVID-19 wave in Italy and to investigate biomarkers of coagulation and endothelial perturbation before and after complete vaccination schedule, twenty-three consecutive adult HIV-positive patients with hemophilia were included. Blood was collected before and two weeks after vaccination. We measured anti-SARS-CoV-2 spike protein antibodies to assess immunogenicity; circulating biomarkers of coagulation (protein C and D-dimer), endothelial perturbation (von Willebrand factor (VWF)) and anti-Platelet Factor 4 (PF4) antibodies were analyzed. Flow-based analysis of thrombus formation was performed in nine patients using a flow-chamber device. Two weeks after completing the vaccination schedule, all patients had anti-spike antibodies values consistent with an effective immunization. Mean (±standard deviation) basal values of protein C and VWF (106 ± 21% and 171 ± 45%, respectively) were not significantly different from data obtained two weeks after the second dose (103 ± 20%, 162 ± 43%, respectively). D-dimer median values (interquartile range) were not significantly different at baseline (442 (603–142) ng/mL) and after the second dose (477 (654–262) ng/mL). Anti-PF4 antibodies were detected in three patients with no associated clinical manifestations. No significant differences were found in flow-based analysis of thrombus formation. Our data demonstrate that in HIV-positive patients with hemophilia, SARS-CoV-2 vaccination is effective and safe, with no effects on coagulation and endothelial perturbation.

Details

Language :
English
ISSN :
20770383
Volume :
12
Issue :
17
Database :
Directory of Open Access Journals
Journal :
Journal of Clinical Medicine
Publication Type :
Academic Journal
Accession number :
edsdoj.0c502ede159f4b03a23a6d00a6bf4cee
Document Type :
article
Full Text :
https://doi.org/10.3390/jcm12175475